FY2026 EPS Estimates for MetaVia Lowered by Zacks Research

MetaVia Inc. (NASDAQ:MTVA – Free Report) – Zacks Research decreased their FY2026 earnings estimates for MetaVia in a research note issued to investors on Wednesday, August 12th. Zacks Research analyst D. Bautz now anticipates that the company will earn ($1.97) per share for the year, down from their previous forecast of ($1.87). The consensus estimate for MetaVia’s current full-year earnings is ($2.79) per share.

Get MetaVia alerts:

MetaVia (NASDAQ:MTVA – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.08).

Several other research firms have also recently weighed in on MTVA. HC Wainwright reaffirmed a “buy” rating on shares of MetaVia in a research report on Friday, July 10th. Wall Street Zen raised MetaVia to a “sell” rating in a research report on Saturday, June 20th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of MetaVia in a research note on Tuesday, July 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, MetaVia presently has a consensus rating of “Hold” and an average target price of $20.00.

Read Our Latest Research Report on MTVA

MetaVia Trading Up 0.7%

MTVA stock opened at $1.49 on Monday. The stock has a 50-day moving average price of $1.58 and a two-hundred day moving average price of $1.67. MetaVia has a 1 year low of $0.97 and a 1 year high of $19.03. The stock has a market cap of $7.69 million, a PE ratio of -0.46 and a beta of 0.95.

Institutional Trading of MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC purchased a new stake in MetaVia Inc. (NASDAQ:MTVA – Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia as of its most recent SEC filing. Institutional investors and hedge funds own 1.37% of the company’s stock.

About MetaVia

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.

Further Reading

• Five stocks we like better than MetaVia
• The AI Boom Is Turning This Cable Maker Into a Stock to Watch
• A Star Investor Just Trimmed Amazon—Here’s What It means
• Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
• Home Depot Analysts See a Path to $375 and Beyond

Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.